Inovio Pharmaceuticals, Inc. (NASDAQ:INO) received a $13.00 price objective from equities researchers at HC Wainwright in a report issued on Tuesday, October 17th. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 122.98% from the stock’s previous close.
Several other research firms have also issued reports on INO. Citigroup Inc. started coverage on shares of Inovio Pharmaceuticals in a report on Friday, October 6th. They issued a “buy” rating and a $10.00 target price on the stock. Aegis restated a “buy” rating and issued a $14.00 target price on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Tuesday, July 11th. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, BidaskClub raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 9th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. Inovio Pharmaceuticals currently has an average rating of “Hold” and an average target price of $19.16.
Inovio Pharmaceuticals (INO) traded up 3.74% on Tuesday, reaching $5.83. The company’s stock had a trading volume of 1,006,252 shares. Inovio Pharmaceuticals has a 52 week low of $5.28 and a 52 week high of $9.86. The stock’s 50 day moving average is $6.21 and its 200-day moving average is $6.63. The firm’s market capitalization is $526.02 million.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The company had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. Inovio Pharmaceuticals’s revenue was up 229.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) earnings per share. Analysts predict that Inovio Pharmaceuticals will post ($0.95) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given a $13.00 Price Target by HC Wainwright Analysts” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/10/28/inovio-pharmaceuticals-inc-ino-pt-set-at-13-00-by-hc-wainwright-2.html.
Large investors have recently bought and sold shares of the company. BlueCrest Capital Management Ltd bought a new stake in shares of Inovio Pharmaceuticals during the second quarter worth about $107,000. PNC Financial Services Group Inc. grew its position in Inovio Pharmaceuticals by 5.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Inovio Pharmaceuticals in the 2nd quarter worth about $171,000. OxFORD Asset Management LLP bought a new stake in Inovio Pharmaceuticals in the 2nd quarter worth about $194,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Inovio Pharmaceuticals in the 2nd quarter worth about $197,000. 25.05% of the stock is owned by institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.